Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts DYN Hot Sheet
Price: $15.77 --0%
Rating Summary:
17 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 15
Rating Summary:
17 Buy, 1 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 15
Join SI Premium – FREE
Oppenheimer analyst Jay Olson upgraded Dyne Therapeutics (NASDAQ: DYN) from Perform to Outperform with a price target of $40.00 (from $11.00).
For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.
Shares of Dyne Therapeutics closed at $18.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WBB Securities Upgrades Turn Therapeutics (TTRX) to Hold
- Range Resources (RRC) PT Raised to $48 at Raymond James
- Lockheed Martin (LMT) PT Raised to $600 at RBC Capital
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
